An administrative study of initial depression treatment reported declining benzodiazepine receptor agonist coprescribing, including lorazepam.
The Alberta study identified 208,988 adults aged 18–65 with a first recorded depression diagnosis and an antidepressant prescription during 2012–2022. It examined initial pharmacotherapy, demographic characteristics, prescriber specialty, and trends over time.
The authors described a decline in benzodiazepine receptor agonist coprescribing after 2016, including reduced use of lorazepam. Lorazepam should be identified as a benzodiazepine adjunct in discussing these results, rather than reclassified as an antidepressant merely because it appears in a depression-treatment dataset.
The authors found broad alignment of initial antidepressant choices with the guideline framework they used. That finding does not establish appropriateness for every patient or resolve the purpose and duration of each benzodiazepine prescription. Recorded dispensing also does not confirm ingestion or benefit.
The study used geographic socioeconomic measures, which may not reflect individual circumstances. Its descriptive design cannot show that a policy or changing clinical attitude caused the trend. For a case review, the value lies in contextualizing prescribing practice while retaining the separate questions of diagnosis, indication, consumption, and observed effects.
Original analysis of the supplied journal article, identified as PMC12930663.